Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

NCT06712810 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06712810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
August 27, 2025
Completion date
September 15, 2030
Enrollment
46 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphatic system neoplasm, histiocytic sarcoma, malignant histiocytosis, peripheral t-cell lymphoma, not otherwise specified, primary central nervous system lymphoma, primary cutaneous t-cell non-hodgkin lymphoma, recurrent blastic plasmacytoid dendritic cell neoplasm, recurrent chronic lymphocytic leukemia, recurrent chronic myelomonocytic leukemia, recurrent erdheim-chester disease, recurrent fibroblastic reticular cell sarcoma, recurrent follicular lymphoma, recurrent histiocytic sarcoma, recurrent interdigitating dendritic cell sarcoma, recurrent langerhans cell histiocytosis, recurrent lymphoplasmacytic lymphoma, recurrent myelodysplastic syndrome, recurrent myelofibrosis, recurrent rosai-dorfman-destombes disease, recurrent small lymphocytic lymphoma, recurrent waldenstrom macroglobulinemia, refractory blastic plasmacytoid dendritic cell neoplasm, refractory chronic lymphocytic leukemia, refractory chronic myelomonocytic leukemia, refractory erdheim-chester disease, refractory fibroblastic reticular cell sarcoma, refractory follicular lymphoma, refractory histiocytic sarcoma, refractory interdigitating dendritic cell sarcoma, refractory langerhans cell histiocytosis, refractory lymphoplasmacytic lymphoma, refractory myelodysplastic syndrome, refractory myelofibrosis, refractory rosai-dorfman-destombes disease, refractory small lymphocytic lymphoma, refractory waldenstrom macroglobulinemia, rosai-dorfman-destombes disease